AOA Dx secures $17 Million to revolutionize the diagnosis of ovarian cancer with early detection and high accuracy, and to expand their GlycoLocate™ Platform to target a broader range of cancers
AOA Dx is announcing an oversubscribed $17 million round led by Good Growth Capital with participation from leading investors including RH Capital, Y Combinator, Astia Fund, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, and FemHealth Ventures, along with strategic diagnostic investors, including Labcorp Venture Fund. Several funds invested for the second time, underpinning the continuous success of AOA Dx across the last year.